Vitamin D and prostate cancer.
Our findings demonstrate the presence of VDR in various human prostate cancer cell lines and in primary cultures derived from normal, BPH and prostate cancer. In addition, 1,25-D induced several bioresponses in these cells including growth inhibition and PSA stimulation. Based on examples in many different malignant cells as well as our data in prostate cells, that vitamin D is anti-proliferative and promotes cellular maturation, it seem clear that vitamin D must be viewed as an important cellular modulator of growth and differentiation if addition to its classical role as regulator of calcium homeostasis. In this respect, vitamin D has the potential to have beneficial actions on various malignancies including prostate cancer. Its ultimate role in prostate cancer remains to be determined, but 1,25-D may prove useful in chemoprevention and/or differentiation therapy. We believe the data currently available provide the basis for an optimistic view on the possible use of vitamin D to treat prostate cancer in patients and that further investigation is clearly warranted to better define its potential therapeutic utility.
Feldman
D
D
Department of Medicine, Stanford University School of Medicine, California 94305-5103, USA.
Skowronski
R J
RJ
Peehl
D M
DM
D002117:Calcitriol / Q000031:analogs & derivatives / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D018167:Receptors, Calcitriol / Q000502:physiology; D014407:Tumor Cells, Cultured; D014807:Vitamin D / Q000494:pharmacology / Q000502:physiology*
D018167:Receptors, Calcitriol; D014807:Vitamin D; D002117:Calcitriol